Effects of cisplatin, α-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines

Journal of Oral Pathology and Medicine

Volumn 36, Issue 3, 2007, Pages 177-183

  Sundelin, Kaarina ^a,b   Roberg, Karin ^a   Grénman, Reidar ^c   Håkansson, Leif ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

interferon; 13 cis retinoic acid; Apoptosis; Cisplatin; EGFR; Fas (CD95); ICAM 1; Oral cancer

Indexed keywords

ALPHA INTERFERON; CASPASE 3; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIBODY; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; ISOTRETINOIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-ALPHA; ISOTRETINOIN; MOUTH NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846997837     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2006.00503.x     Document Type: Article

References (31)

1. Resser JR, Carbone DP. Immunotherapy of head and neck cancer. Curr Opin Oncol 1998; 10: 226-32.
2. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Int Arch Allergy Immunol 2003; 132: 294-309.
3. Huang GT, Zhang X, Park NH. Increased ICAM-1 expression in transformed human oral epithelial cells: molecular mechanism and functional role in peripheral blood mononuclear cell adhesion and lymphokine-activated-killer cell cytotoxicity. Int J Oncol 2000; 17: 479-86.
4. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13: 135-47.
5. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
6. Pomerantz RG, Grandis JR. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31: 734-43.
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
8. Chai RL, Grandis JR. Advances in molecular diagnostics and therapeutics in head and neck cancer. Curr Treat Options Oncol 2006; 7: 3-11.
9. Zadogzdon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better. Int J Oncol 2001; 18: 417-24.
10. Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol 2003; 3: 11105-19.
11. Spreafico F, Vecchi A. The immunomodulatory activity of certain cancer chemotherapeutic agents. In: Mihich E, Sakurai Y, eds. Biological responses in cancer. Immunomodulation by anticancer drugs, Vol. 3. New York: Plenum, 1985; 131-54.
12. Kleinerman ES, Zwelling LA. Effects of cisplatin, bleomycin and DTIC on immune function in vitro and in vivo. In: Mitchell MS, Fahey JL, eds. Immune suppression and modulation. Clinics in immunology and allergy, Vol. 4, No. 2. London: Saunders, 1984; 279-94.
13. Schlaefli E, Ehrke MJ, Mihich E. The effects of dichlorotrans-dihydroxy- bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology 1983; 6: 107-22.
14. Zoon KC, Belisz J, Miller D. Human interferon alpha family: protein structure and function. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Jr, Hughes TK, Jr, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK, eds. Interferon: principles and medical applications. Galveston, TX: The University of Texas, Medical Branch, Department of Microbiology, 1992; 95-105.
15. Sporn MB, Roberts AB, Goodman DS. The retinoids. Biology, chemistry and medicine, 2nd edn. New York: Raven Press, 1994.
16. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of head and neck. N Engl J Med 1990; 323: 795-801.
17. Lansford CD, Grénman R, Bier H, et al. Head and neck cancers. In: Masters J, Palsson B, eds. Human Cell Culture, Vol. 2, Cancer Cell Lines, Part 2. Dordrecht: Kluwer Academic Press, 1999; 185-255.
18. Pekkola-Heino K, Servomaa K, Kiuru A, Grénman R. Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma. Acta Otolaryngol 1996; 116: 341-4.
19. Hauser U, Balz V, Carey TE, et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 2002; 24: 868-73.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
21. Chen Z, Ke LD, Yaun XH, Adler-Storthz K. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 2000; 20: 899-902.
22. Matsuoka H, Eura M, Chikamatsu K, et al. Low doses of anticancer drugs increase susceptibility of tumor cells to lysis by autologous killer cells. Anticancer Res 1995; 15: 87-92.
23. Kuwahara D, Tsusumi K, Kobayashi T, Hasunuma T, Nishioka K. Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Lett 2000; 148: 65-71.
24. Jiang S, Song MJ, Shin EC, Lee MO, Kim SJ, Park JH. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology 1999; 29: 101-10.
25. Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces Fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 2000; 59: 336-43.
26. Iwase M, Watanabe H, Kondo G, Ohashi M, Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to Fas-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 2003; 106: 619-25.
27. Müller M, Wilder S, Bannasch D, et al. P53 activates the CD95 (Apo-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 11: 2033-45.
28. Li Y, Raffo AJ, Drew L, et al. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143. Cancer Res 2003; 63: 1527-33.
29. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032-40.
30. Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998; 282: 290-3.
31. Kim JH, Ajaz M, Lokshin A, Lee YJ. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosisinducing ligand and cisplatin-augmented apoptosis. Clin Cancer Res 2003; 9: 3134-41.